Structure-activity relationships of anti-HIV-1 peptides with disulfide linkage between D- and L-cysteine at positions i and i+3, respectively, derived from HIV-1 gp41 C-peptide

被引:13
作者
Lee, MK
Kim, HK
Lee, TY
Hahm, KS
Kim, KL
机构
[1] System Proteom Res Ctr, Korea Res Inst Biosci & Biotechnol, Taejon 305600, South Korea
[2] Chosun Univ, Res Ctr Prot Mat, Kwangju 501759, South Korea
[3] Sungkyunkwan Univ, Dept Biol Sci, Suwon 440746, South Korea
关键词
anti-HIV agents; HIV-1; HIV envelope protein gp41; receptors; HIV; structure-activity relationship; viral fusion proteins;
D O I
10.1038/emm.2006.3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The constrained a-helical structure of a C-peptide is useful for enhancing anti-HIV-1 activity. The i and i+3 positions in an alpha-helical structure are located close together, therefore D-Cys (dC) and L-Cys (C) were introduced at the positions, respectively, to make a dC-C disulfide bond in 28mer C-peptides. Accordingly, this study tested whether a dC-C disulfide bond would increase the alpha-helicity and anti-HIV-1 activity of peptides. A C-peptide can be divided into three domains, the N-terminal hydrophobic domain (HPD), middle interface domain (IFD), and C-terminal hydrogen domain (HGD), based on the binding property with an N-peptide. In general, the dC-C modifications in HPD enhanced the anti-HIV-1 activity, while those in IFD and HGD resulted in no or much less activity. The modified peptides with no activity clearly showed much less alpha-helicity than the native peptides, while those with higher activity showed an almost similar or slightly increased a-helicity. Therefore, the present results suggest that the introduction of a dC-C bridge in the N-terminal hydrophobic domain of a C-peptide may be useful for enhancing the anti-HIV-1 activity.
引用
收藏
页码:18 / 26
页数:9
相关论文
共 27 条
[1]   Core structure of gp41 from the HIV envelope glycoprotein [J].
Chan, DC ;
Fass, D ;
Berger, JM ;
Kim, PS .
CELL, 1997, 89 (02) :263-273
[2]   Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target [J].
Chan, DC ;
Chutkowski, CT ;
Kim, PS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (26) :15613-15617
[3]   HIV entry and its inhibition [J].
Chan, DC ;
Kim, PS .
CELL, 1998, 93 (05) :681-684
[4]   The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates [J].
Choe, H ;
Farzan, M ;
Sun, Y ;
Sullivan, N ;
Rollins, B ;
Ponath, PD ;
Wu, LJ ;
Mackay, CR ;
LaRosa, G ;
Newman, W ;
Gerard, N ;
Gerard, C ;
Sodroski, J .
CELL, 1996, 85 (07) :1135-1148
[5]   HIGH-TITER PACKAGING CELLS PRODUCING RECOMBINANT RETROVIRUSES RESISTANT TO HUMAN SERUM [J].
COSSET, FL ;
TAKEUCHI, Y ;
BATTINI, JL ;
WEISS, RA ;
COLLINS, MKL .
JOURNAL OF VIROLOGY, 1995, 69 (12) :7430-7436
[6]   A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors [J].
Doranz, BJ ;
Rucker, J ;
Yi, YJ ;
Smyth, RJ ;
Samson, M ;
Peiper, SC ;
Parmentier, M ;
Collman, RG ;
Doms, RW .
CELL, 1996, 85 (07) :1149-1158
[7]   Mechanisms of viral membrane fusion and its inhibition [J].
Eckert, DM ;
Kim, PS .
ANNUAL REVIEW OF BIOCHEMISTRY, 2001, 70 :777-810
[8]   Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region [J].
Eckert, DM ;
Kim, PS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (20) :11187-11192
[9]   HIV-1 Entry Cofactor: Functional cDNA Cloing of a Seven-Transmembrane, G protein-Coupled Receptor [J].
Feng, Yu ;
Broder, Christopher C. ;
Kennedy, Paul E. ;
Berger, Edward A. .
JOURNAL OF IMMUNOLOGY, 2011, 186 (11) :872-877
[10]   Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41 [J].
Jiang, SB ;
Debnath, AK .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 269 (03) :641-646